Cara Therapeutics (CARA): where does the stock go from here?

12:30 pm ET, 25 May 2018

ValuEngine upgraded Cara Therapeutics (NASDAQ: CARA) today, and the stock shot up 11% in mid-day trading.  What is the CARA stock price forecast?  

Just about a year ago, the biotech announced disappointing results for its lead candidate, CR845, in a phase 2b study targeting treatment of pain in osteoarthritis (OA) patients.

The tide has now turned: Cara is evaluating an injection of CR845 in a phase-3 clinical study targeting treatment of chronic kidney disease-associated pruritus (CKD-aP) patients.

The biotech is also pursuing phase 1 and phase 2 clinical studies of an oral version of the drug in treating CKD-aP patients.  

The market is upbeat about the prospect for CR845: Cara plans to announce results within next month from its phase 3 study of an intravenous version of CR845 in treating post-operative pain in patients undergoing abdominal surgery.

Based on the technical analysis, the short-term sentiment for the stock looks quite strong.  The mid-term sentiment is somewhat bleak, while long-term there are many opportunities for Cara Therapeutics to grow.  


Based on Finstead research, CARA average analyst price target is $25.14 (visit Finstead and type "CARA price target" to get the latest data).  

Over the last year, CARA returned +3.66%. This return is lower than Biotechnology sector (60.35%), Healthcare industry (45.26%), S&P 500 (12.95%) returns.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finny Bites, please send us an email at hi@askfinny.com.

Cara Therapeutics, Inc. (CARA) Stock Guide

Updated at: 3:31 am ET, 12 Jul 2020

Before we start: if you're looking for CARA stock price, you can quickly find it out by visiting Finny and typing "CARA quote". If you're looking for a quick scoop on CARA stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "CARA". You'll get all this info in one place. Or you can just type "CARA news" to get the latest stock news.

Looking to buy or sell Cara Therapeutics, Inc. (CARA)? Interested in getting the full scoop on CARA, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this CARA stock guide, we'll address key questions about CARA, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are CARA earnings?
2. When is CARA earnings date?
3. What is CARA stock forecast (i.e., prediction)?
4. CARA buy or sell? What is CARA Finny Score?
5. What are the reasons to buy CARA? Why should I buy CARA stock?
6. What are the reasons to sell CARA? Why should I sell CARA stock?
7. What are CARA key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are CARA earnings?

CARA trailing 12-month earnings per share (EPS) is -$2.49.

2. When is CARA earnings date?

CARA earnings date is May 11, 2020.

Analyst Predictions

3. What is CARA stock forecast (i.e., prediction)?

Based on CARA analyst price targets, CARA stock forecast is $32.44 (for a year from now). That means the average analyst price target for CARA stock is $32.44. The prediction is based on 7 analyst estimates.

The low price target for CARA is $19.00, while the high price target is $39.00.

CARA analyst rating is Buy.

Analysis

4. CARA buy or sell? What is CARA Finny Score?

#{finnyScore:50}Our quantitative analysis shows 4 reasons to buy and 4 reasons to sell CARA, resulting in Finny Score of 50.

5. What are the reasons to buy CARA? Why should I buy CARA stock?

Here are the reasons to buy CARA stock:

6. What are the reasons to sell CARA? Why should I sell CARA stock?

Let's look at the reasons to sell CARA stock (i.e., the bear case):

  • CARA stock price ($17.63) is close to the 52-week high ($17.88). Perhaps now is a good time to sell? See CARA price chart.
  • CARA quarterly revenue growth was -18.50%, lower than the industry and sector average revenue growth (0.52% and 1.16%, respectively). See CARA revenue growth chart.
  • CARA short share of float is 8.02%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock. See CARA short share of float chart.
  • CARA short interest (days to cover the shorts) ratio is 6.62. The stock garners more short interest than the average industry, sector or S&P 500 stock. See CARA short interest ratio chart.

Key Stats

7. What are CARA key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for CARA:

Metrics CARA
Price $17.11
Average Price Target / Upside $32.44 / 89.60%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 55
Market Cap $705.69M
Forward P/E Ratio -6.73
Price/Book Ratio 35.49
Revenue (TTM) $19.89M
YoY Quarterly Revenue Growth -18.50%
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finny Bites, please send us an email at hi@askfinny.com.

Use Finny to ask any finance or investment question. Big or small. Personal or general.
Follow Us